Ocular Therapeutix, Inc.
OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.47
Price+14.46%
$1.07
1Y
Price
Market Cap
$1.844b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-457.2%
EBITDA Margin-488.0%
Net Profit Margin-430.8%
Free Cash Flow Margin-457.2%
EBITDA Margin-488.0%
Net Profit Margin-430.8%
Free Cash Flow MarginRevenue
$51.823m
-18.5%
1y CAGR+1.4%
3y CAGR+5.6%
5y CAGREarnings
-$265.939m
-37.4%
1y CAGR-63.6%
3y CAGR-293.7%
5y CAGREPS
-$1.42
-18.0%
1y CAGR-14.3%
3y CAGR-10.4%
5y CAGRBook Value
$654.310m
$808.057m
Assets$153.747m
Liabilities$79.783m
DebtDebt to Assets
9.9%
-0.3x
Debt to EBITDAFree Cash Flow
-$216.893m
-59.5%
1y CAGR-52.7%
3y CAGR-38.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company